Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist
- PMID:32777318
- PMCID: PMC7413159
- DOI: 10.1016/j.jaad.2020.08.006
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist
Abstract
The new coronavirus, severe acute respiratory syndrome coronavirus 2, is associated with a wide variety of cutaneous manifestations. Although new skin manifestations caused by COVID-19 are continuously being described, other cutaneous entities should also be considered in the differential diagnosis, including adverse cutaneous reactions to drugs used in the treatment of COVID-19 infections. The aim of this review is to provide dermatologists with an overview of the cutaneous adverse effects associated with the most frequently prescribed drugs in patients with COVID-19. The skin reactions of antimalarials (chloroquine and hydroxychloroquine), antivirals (lopinavir/ritonavir, ribavirin with or without interferon, oseltamivir, remdesivir, favipiravir, and darunavir), and treatments for complications (imatinib, tocilizumab, anakinra, immunoglobulins, corticosteroids, colchicine and low molecular weight heparins) are analyzed. Information regarding possible skin reactions, their frequency, management, and key points for differential diagnosis are presented.
Keywords: COVID-19 drug treatment; drug eruptions; drug-related side effects and adverse reactions; review.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
- Cutaneous manifestations in COVID-19: Lessons learned from current evidence.Suchonwanit P, Leerunyakul K, Kositkuljorn C.Suchonwanit P, et al.J Am Acad Dermatol. 2020 Jul;83(1):e57-e60. doi: 10.1016/j.jaad.2020.04.094. Epub 2020 Apr 24.J Am Acad Dermatol. 2020.PMID:32339706Free PMC article.No abstract available.
- Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.Uzunova K, Filipova E, Pavlova V, Vekov T.Uzunova K, et al.Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.Biomed Pharmacother. 2020.PMID:32861965Free PMC article.Review.
- Psychopharmacology of COVID-19.Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL.Bilbul M, et al.Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.Psychosomatics. 2020.PMID:32425246Free PMC article.Review.
- Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.Panda PK, Bandyopadhyay A, Singh BC, Moirangthem B, Chikara G, Saha S, Bahurupi YA.Panda PK, et al.Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.Trials. 2020.PMID:33081849Free PMC article.Clinical Trial.
- SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.Costanzo M, De Giglio MAR, Roviello GN.Costanzo M, et al.Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.Curr Med Chem. 2020.PMID:32297571
Cited by
- Effects of Vitamin C on the Oral-Nasal Mucosal Damage Caused by Favipiravir in Old and Young Rats.Kurt Y, Özmen Ö.Kurt Y, et al.Cureus. 2022 Sep 5;14(9):e28796. doi: 10.7759/cureus.28796. eCollection 2022 Sep.Cureus. 2022.PMID:36225521Free PMC article.
- Defining the short-term and long-term skin manifestations of COVID-19: insights after more than three years of the pandemic.Ică OM, Mitroi G, Ianoşi SL, Tutunaru CV, Leru PM, Matei D, Avramescu ET, Tănasie CA, Mitroi IB, Neagoe CD, Cazacu SM.Ică OM, et al.Rom J Morphol Embryol. 2023 Jul-Sep;64(3):291-304. doi: 10.47162/RJME.64.3.01.Rom J Morphol Embryol. 2023.PMID:37867347Free PMC article.Review.
- Current Perspectives on Severe Drug Eruption.Zhang J, Lei Z, Xu C, Zhao J, Kang X.Zhang J, et al.Clin Rev Allergy Immunol. 2021 Dec;61(3):282-298. doi: 10.1007/s12016-021-08859-0. Epub 2021 Jul 17.Clin Rev Allergy Immunol. 2021.PMID:34273058Free PMC article.Review.
- Mucocutaneous lesions associated with SARS-CoV-2 infection (Review).Toader MP, Branisteanu DC, Glod M, Esanu IM, Branisteanu CI, Capsa MS, Dimitriu A, Nicolescu AC, Pinzariu AC, Branisteanu DE.Toader MP, et al.Exp Ther Med. 2022 Apr;23(4):258. doi: 10.3892/etm.2022.11183. Epub 2022 Feb 3.Exp Ther Med. 2022.PMID:35251324Free PMC article.Review.
- Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection.Aryanian Z, Balighi K, Hatami P, Tootoonchi NM, Goodarzi A, Mohseni Afshar Z.Aryanian Z, et al.Clin Case Rep. 2022 Apr 18;10(4):e05667. doi: 10.1002/ccr3.5667. eCollection 2022 Apr.Clin Case Rep. 2022.PMID:35449768Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources